New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
18:47 EDTVRNT, FIVE, RLD, HALO, AXAS, PVH, NVAX, TSLOn The Fly: After Hours Movers
UP AFTER EARNINGS: Verint Systems (VRNT), up 6.78% after reporting better than expected first quarter results and raising fiscal 2015 guidance... Five Below (FIVE), up 2.87% after reporting quarterly results... RealD (RLD), up 1.7%. ALSO HIGHER: Halozyme Therapeutics (HALO), up 13.24% after the FDA removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial... Abraxas Petroleum (AXAS), up 6.67% after raising its fiscal 2014 production guidance to 5,500-5,700 Boepd. DOWN AFTER EARNINGS: PVH Corp. (PVH), down 6.26% after lowering fiscal 2014 guidance... ALSO LOWER: Novavax (NVAX), down 8.66% after filing to sell $100M of common stock... Trina Solar (TSL), down 3.79%.
News For VRNT;FIVE;RLD;HALO;AXAS;PVH;NVAX;TSL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
10:15 EDTPVHHigh option volume stocks
Subscribe for More Information
06:38 EDTTSLEU sets emissions, renewable energy targets, NY Times says
Subscribe for More Information
October 22, 2014
09:53 EDTTSLCredit Suisse Events at Solar Power International
Credit Suisse holds meetings in Las Vegas in conjunction with the Solar Power International Conference include ENPH, TSL, CSIQ, SCTY, JASO, HSOL and STRI on October 22.
October 20, 2014
14:22 EDTFIVEFive Below management to meet with BB&T
Meeting to be held in Philadelphia on October 23 hosted by BB&T.
12:36 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
09:04 EDTHALOBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
08:32 EDTHALOHalozyme receives FDA approval for new Hylenex recombinant facilities
Subscribe for More Information
08:14 EDTTSLTrina Solar management to meet with Deutsche Bank
Subscribe for More Information
October 17, 2014
10:00 EDTFIVEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:28 EDTNVAXNovavax management to meet with JPMorgan
Subscribe for More Information
08:11 EDTFIVEFive Below initiated with a Hold at Stifel
Subscribe for More Information
October 16, 2014
11:15 EDTNVAXHigh option volume stocks
Subscribe for More Information
October 15, 2014
08:40 EDTNVAXNovavax RSV F Vaccine study evoked polyclonal antibody response
Novavax announced that its RSV F-protein nanoparticle vaccine candidate, or RSV F Vaccine, evoked a polyclonal antibody response to antigenic site II, the same site targeted by the monoclonal antibody palivizumab, resulting in protection from an RSV challenge in an animal model. Researchers at Novavax reported these findings in an online paper published by Vaccine titled: "An insect cell derived respiratory syncytial virus F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization." Greg Glenn, SVP, Research and Development at Novavax stated, "This study further characterizes the immune response to our RSV F Vaccine, including the production of both polyclonal palivizumab competing antibodies that target antigenic site II, as well as other neutralizing antigenic sites on the F-protein. In addition, our ability to assess the safety of our RSV F Vaccine relative to Lot 100 formalin inactivated vaccine, which is known to cause disease enhancement, and to demonstrate that our vaccine's efficacy is equivalent or better than palivizumab, gives us greater confidence that our RSV vaccine candidate will be both safe and effective."
October 14, 2014
08:40 EDTNVAXNovavax initiates Phase 2 clinical trial of RSV F vaccine
Novavax announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus, or RSV, F-protein nanoparticle vaccine candidate, in healthy elderly subjects. The trial is a randomized, observer-blinded, placebo-controlled Phase 2 study scheduled to enroll 1,600 elderly subjects at ten sites in the United States. The trial will evaluate the incidence of all respiratory illnesses due to RSV, including medically-attended respiratory illnesses due to RSV, and hospitalizations for respiratory illness due to RSV in community-living elderly adults who have been treated with placebo. The study will also evaluate the safety and immunogenicity of a 135g dose of the RSV F Vaccine compared with placebo. The trial will also estimate the efficacy of the RSV F Vaccine in reducing the incidence of respiratory illnesses due to RSV.
08:30 EDTVRNTVerint Systems checks show good deal momentum, says FBR Capital
Subscribe for More Information
07:03 EDTTSLTrina Solar's monocrystalline honey module seats world record for power output
Subscribe for More Information
06:42 EDTTSLPV modules with solar-grade wafers to account for 89% of capacity, DigiTimes says
Solarbuzz says solar photovoltaic modules using solar-grade wafers will account for 89% of solar capacity forecast to be installed in 2014, reports DigiTimes. Thin-filmed panel makers will supply nearly 8% of end-market demand in 2014, while premium cyrstalline silicon suppliers making up the remaining 3% share. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL), Panasonic (PCRFY) and Yingli Green Energy (YGE). Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use